Kendra Sweet MD, MS

Kendra Sweet, MD, MS, is currently an associate member in the Malignant Hematology Faculty at Moffitt Cancer Center in Tampa, FL, as well as a Senior Medical Director in Hematology at BeiGene. She completed her medical education at the Medical College of Virginia – Virginia Commonwealth University in Richmond, VA. Her internal medicine residency was completed at the University of Arizona in Tucson, AZ, and her hematology and medical oncology fellowship training was done at Moffitt Cancer Center/The University of South Florida. She was awarded a 3-year career development award from the Leukemia and Lymphoma Society in order to support her research efforts for the first 3 years on faculty. She is board-certified in medical oncology, hematology, and internal medicine.

Dr. Sweet has been a clinical investigator with a focus on AML and CML. She has opened 2 multi-center Phase II clinical trials for which she has functioned as the national PI. These 2 trials build on her previous work with ruxolitinib in combination with TKIs for the treatment of the chronic phase of chronic myeloid leukemia (CML). One trial, which was run through the Southwest Oncology Group Leukemia Committee, has completed accrual, and the primary endpoint has read out. The second is run through the J Khoury CML Consortium. In addition to this, she has been the PI on a number of sponsored clinical trials in AML and BPDCN, and much of her work has led to abstract submissions and presentations at ASH, ASCO, and the European School of Hematology Annual Meetings.

In 2023, Dr. Sweet switched her role at Moffitt Cancer Center to a part-time academic appointment and has taken a full-time position as the Senior Medical Director in Hematology with BeiGene. In this role, she oversees the development and conduct of clinical trials in AML and CLL using BeiGene assets.

In spite of leaving her full-time position, Dr. Sweet has maintained a clinic at Moffitt Cancer Center in order to continue treating patients with CML. This is being done because of her love of patient care and strong desire to improve the lives of people living with CML. Outside of this, she has remained involved with the iCMLf and the J Khoury Cure CML Consortium in order to help to continue to move the field forward for patients.